Business Wire

NY-PYRAMID-ANALYTICS

Share
Pyramid Analytics Wins 2022 Ventana Research Digital Innovation Award in Analytics Category

Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, today announced that the company won a 2022 Ventana Research Digital Innovation Award . The company’s Pyramid Decision Intelligence Platform was selected over finalists Qlik Active Intelligence and H2O AI Cloud in the Analytics category of the 15th edition of the respected analyst firm’s awards program. The award is given to the technology vendor that best exemplifies innovation in any use or application of analytics across business and/or IT. The Business Intelligence and Analytics segment of the global software market is highly competitive. There are an estimated 120 vendors in the space.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005330/en/

Key Points:

  • The Pyramid Decision Intelligence Platform debuts as a Winner in the Ventana Research Digital Innovation Awards.
  • Pyramid Analytics took top honor in the Analytics category of the 15th Annual Ventana Research Digital Innovation Awards for its ground-breaking Pyramid Decision Intelligence Platform.
  • The Pyramid Decision Intelligence Platform surpassed Qlik Active Intelligence and an AI development and performance management platform from H2O AI.
  • Click here to schedule a demo of the Pyramid Decision Intelligence Platform .

The Pyramid Decision Intelligence Platform Helps Organizations Innovate

“It is with our greatest honor that our market advisory and research firm recognizes the winners of the 15th annual Ventana Research Digital Innovation Awards for their innovation in technology that provides the readiness and resilience for the best and worst of times,” said Mark Smith , CEO and Chief Research Officer, Ventana Research. “The technology industry continues to deliver impact and value, from intelligence and automation with collaboration and engagement blended into products and technology that help organizations innovate and simplify. Congratulations to the winners and their success.”

Ventana Research Digital Innovation Awards identify the top technologies and products that have the most striking impact in their respective markets, recognizing pioneering vendors that contribute advancements in technology, drive change and increase value for organizations worldwide. This year’s finalists represent a significant wave of technological advancements in use of AI (artificial intelligence) and ML (machine learning) infused across tools and applications demonstrating substantive advancements, that from Ventana’s analysis, have the most significant impact to the technology industry.

Decision Intelligence is the Next Big Data Analytics Innovation

The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep , Business Analytics , and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.

The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.

Quotes

Omri Kohl , Chief Executive Officer and Co-Founder, Pyramid Analytics: “The entire Pyramid team is elated to win the 2022 Ventana Research Digital Innovation Award for Analytics. Ventana analysts, led by Mark Smith, have witnessed, evaluated, and guided the evolution of data analytics for the better part of two decades. Their acknowledgement that decision intelligence represents what a modern analytics solution should be – a unified, enterprise scale platform that is engineered and works for advanced data scientists, the C-Suite, and line of business alike without compromise – validates our mission and motivates us. Heartfelt appreciation to the Ventana team, the Pyramid family, and our customers and partners who have believed in and stood by us.”

David Menninger , SVP & Research Director at Ventana Research: “For too long, analytics vendors have focused on delivering information rather than guiding the decision-making process. In this year's 15th Annual Digital Innovation Award for Analytics, we recognized Pyramid Analytics for its focus on decision intelligence and its platform using AI and Machine Learning across data and analytics to help organizations and individuals evaluate the trade-offs between different decisions and anticipated outcomes.”

About Pyramid Analytics

Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for anyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo .

Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners , Jerusalem Venture Partners (JVP), Sequoia Capital , and Viola Growth . Learn more at Pyramid Analytics .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye